Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
Phase 1
- Conditions
- Amphetamine-Related Disorders
- Registration Number
- NCT00033072
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.
- Detailed Description
To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg \& 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
- Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals
- Be able to verbalize understanding of consent form; provide written informed consent
Exclusion Criteria
- Please contact site for more information
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pharmacokinetic assessment safety of selegiline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
UCLA Integrated Substance Abuse Program
🇺🇸Los Angeles, California, United States